Literature DB >> 7703207

Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid.

M J Elder1, S Lightman, J K Dart.   

Abstract

AIMS/
BACKGROUND: Ocular cicatricial pemphigoid (OCP) can present with severe conjunctival inflammation that requires systemic immunosuppression to avoid serious ocular morbidity. This study aimed to assess the clinical response to cyclophosphamide and short term, high dose prednisolone in this group of patients.
METHODS: A prospective, unmasked study assessed patients presenting with either 'severe' ocular inflammation (n = 4) or 'marked' or 'severe' ocular inflammation that had failed to respond to other systemic immunosuppression (n = 6). Nineteen inflamed eyes of 10 consecutive patients were enrolled.
RESULTS: The ocular inflammation resolved in 15 eyes in a mean time of 2.4 months. Two eyes perforated despite treatment and one patient was unable to tolerate the medication. Progressive cicatrisation occurred in 21%.
CONCLUSION: Cyclophosphamide and short term, high dose prednisolone are effective in severe inflammation caused by OCP but may not completely prevent cicatrisation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7703207      PMCID: PMC505076          DOI: 10.1136/bjo.79.3.264

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  18 in total

1.  Autoimmune phenomena in ocular cicatricial pemphigoid.

Authors:  B J Mondino; A N Ross; B S Rabin; S I Brown
Journal:  Am J Ophthalmol       Date:  1977-04       Impact factor: 5.258

2.  Severe cystitis induced by cyclophosphamide. Role of surgical management.

Authors:  B M Berkson; L G Lome; I Shapiro
Journal:  JAMA       Date:  1973-08-06       Impact factor: 56.272

3.  Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.

Authors:  R S Rogers; J R Seehafer; H O Perry
Journal:  J Am Acad Dermatol       Date:  1982-02       Impact factor: 11.527

4.  Ocular cicatricial pemphigoid.

Authors:  B J Mondino; S I Brown
Journal:  Ophthalmology       Date:  1981-02       Impact factor: 12.079

Review 5.  Immunosuppressive and cytotoxic drugs in dermatology.

Authors:  P I Dantzig
Journal:  Arch Dermatol       Date:  1974-09

6.  Immunosuppressive therapy for progressive ocular cicatricial pemphigoid.

Authors:  C S Foster; L A Wilson; M B Ekins
Journal:  Ophthalmology       Date:  1982-04       Impact factor: 12.079

7.  The acute manifestations of ocular cicatricial pemphigoid: diagnosis and treatment.

Authors:  B J Mondino; S I Brown; S Lempert; M S Jenkins
Journal:  Ophthalmology       Date:  1979-04       Impact factor: 12.079

Review 8.  Bullous and cicatricial pemphigoid. Clinical, histopathologic, and immunopathologic correlations.

Authors:  J R Person; R S Rogers
Journal:  Mayo Clin Proc       Date:  1977-01       Impact factor: 7.616

9.  Autoimmune phenomena of the external eye.

Authors:  B J Mondino; S I Brown; B S Rabin
Journal:  Ophthalmology       Date:  1978-08       Impact factor: 12.079

10.  Immunosuppressive therapy in ocular cicatricial pemphigoid.

Authors:  B J Mondino; S I Brown
Journal:  Am J Ophthalmol       Date:  1983-10       Impact factor: 5.258

View more
  12 in total

Review 1.  Autoimmune bullous diseases: ocular manifestations and management.

Authors:  Caroline Laforest; Shyamala C Huilgol; Robert Casson; Dinesh Selva; Igal Leibovitch
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Eosinophil granule proteins expressed in ocular cicatricial pemphigoid.

Authors:  A Heiligenhaus; J Schaller; S Mauss; S Engelbrecht; J E Dutt; C S Foster; K P Steuhl
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

Review 3.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

4.  Progression of disease in ocular cicatricial pemphigoid.

Authors:  M J Elder; W Bernauer; J Leonard; J K Dart
Journal:  Br J Ophthalmol       Date:  1996-04       Impact factor: 4.638

5.  Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.

Authors:  Gérôme Bohelay; Marina Alexandre; Christelle Le Roux-Villet; Ishaï Sitbon; Serge Doan; Isaac Soued; Jason Shourick; Laurie Rousset; Benoît Mellottee; Michel Heller; Nicole Lièvre; Coralie Zumelzu; Florence Morin; Sabine Grootenboer-Mignot; Eric Gabison; Frédéric Caux; Catherine Prost-Squarcioni; Philippe Musette
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

6.  Cyclophosphamide for ocular inflammatory diseases.

Authors:  Siddharth S Pujari; John H Kempen; Craig W Newcomb; Sapna Gangaputra; Ebenezer Daniel; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; C Stephen Foster
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

Review 7.  [Mucous membrane pemphigoid with ocular involvement. Part II: therapy].

Authors:  T Meyer-ter-Vehn; E Schmidt; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-04       Impact factor: 1.059

Review 8.  Ocular cicatricial pemphigoid: manifestations and management.

Authors:  John H Chang; Peter J McCluskey
Journal:  Curr Allergy Asthma Rep       Date:  2005-07       Impact factor: 4.919

9.  Evaluation of early and late presentation of patients with ocular mucous membrane pemphigoid to two major tertiary referral hospitals in the United Kingdom.

Authors:  G P Williams; C Radford; P Nightingale; J K G Dart; S Rauz
Journal:  Eye (Lond)       Date:  2011-07-29       Impact factor: 3.775

10.  Treatment strategies in mucous membrane pemphigoid.

Authors:  Ann G Neff; Matthew Turner; Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.